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TYK2-induced phosphorylation 
of Y640 suppresses STAT3 
transcriptional activity
Raffaele Mori1,3, Joris Wauman1,3, Laura Icardi  1,3,4, José Van der Heyden1,3,  
Lode De Cauwer  1,3,5, Frank Peelman1,3, Karolien De Bosscher1,2,3,6 & Jan Tavernier1,3,6
STAT3 is a pleiotropic transcription factor involved in homeostatic and host defense processes in the 
human body. It is activated by numerous cytokines and growth factors and generates a series of cellular 
effects. Of the STAT-mediated signal transduction pathways, STAT3 transcriptional control is best 
understood. Jak kinase dependent activation of STAT3 relies on Y705 phosphorylation triggering a 
conformational switch that is stabilized by intermolecular interactions between SH2 domains and the 
pY705 motif. We here show that a second tyrosine phosphorylation within the SH2 domain at position 
Y640, induced by Tyk2, negatively controls STAT3 activity. The Y640F mutation leads to stabilization of 
activated STAT3 homodimers, accelerated nuclear translocation and superior transcriptional activity 
following IL-6 and LIF stimulation. Moreover, it unlocks type I IFN-dependent STAT3 signalling in cells 
that are normally refractory to STAT3 transcriptional activation.
The signal transducers and activators of transcription (STATs) are transcription factors able to carry specific sig-
nals from the cell membrane to the nucleus and induce gene transcription. The STAT protein family comprises 
seven different members (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6) that are encoded by dis-
tinct genes1. All STATs are characterized by six conserved domains: an N-terminal domain (NTD), a coiled-coil 
domain (CCD), a DNA-binding domain, a linker domain (LD), a Src homology 2 domain (SH2) and a C-terminal 
transactivation domain (TAD). Different ligands can activate STAT proteins, including growth factors, hor-
mones and cytokines. Also mutated kinases, observed in neoplastic disease, are able to activate STAT proteins2–4. 
Abnormal STAT signalling may lead to chronic inflammatory diseases and cancer development5,6. Therefore the 
role of STATs in numerous physiological and pathological processes including cell survival, immunity, angiogen-
esis, metastasis and oncogenesis is being investigated in great detail7–11. According to the canonical model, STATs 
are activated by cell-surface receptors associated with tyrosine kinases of the JAK (Janus Tyrosine Kinase) family. 
JAK members include JAK1, JAK2, JAK3 and TYK27. Following structural analyses of JAKs, four distinct domains 
are identified: an N-terminal FERM domain and an SH2-like domain responsible for binding to the intracellular 
region of the cognate receptor12, followed by a central kinase-like (KL) domain and a C-terminal tyrosine kinase 
(TK) domain. The KL domain harbors an auto- and trans-regulatory activity that either keeps the protein in an 
inactive or low phosphorylated state in absence of ligand13 or stabilizes the enzyme in an activated state upon 
cytokine stimulation14. Upon ligand-binding to the receptor, JAKs are activated by trans-phosphorylation of key 
tyrosines in the activation loop of the TK domain15 and in turn phosphorylate specific tyrosine residues on the 
intracellular domains of the associated receptor chain. This process creates docking sites for the recruitment of 
proteins containing a Src homology 2 (SH2) domain, such as STATs. Upon recruitment to the receptor, STATs 
are phosphorylated and can form activated parallel homo- and hetero-dimers stabilized by reciprocal, inter-
molecular interactions between the phosphotyrosine of one STAT and the SH2 domain of another STAT. These 
homo- and hetero-dimers can subsequently translocate to the nucleus and initiate transcription by binding spe-
cific sites in the promoters of target genes. In non-canonical models, some features differ from the above outlined 
mechanism. For instance, also non-phosphorylated STAT dimers are reported to translocate to the nucleus and 
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contribute to gene regulation16,17. STATs may control gene expression not only as dimers but also as tetramers at 
particular gene promoters18 or even as conglomerates of a higher molecular mass, called “statosomes”19. STAT3 
is known to be abnormally activated in autoimmune diseases, chronic inflammation and in a large percentage 
of human cancers. This is mostly the consequence of aberrant tyrosine phosphorylation by oncogenic receptor 
tyrosine kinases, JAKs and Src family kinases20,21 rather than mutations in STAT3 itself. Similar to the other STAT 
members, STAT3 activity is tightly controlled by posttranslational modifications including phosphorylation at 
Y70522 and S72723, lysine acetylation24–26, methylation27,28, ubiquitination29 and SUMOylation30. A plethora of 
studies identify Y640 as a fundamental residue modulating STAT3 transcriptional activity in response to known 
STAT3 transcriptional activators like interleukin-6 (IL-6) and leukemia inhibitory factor (LIF) and even to type 
I IFNs31–35. Yet, its role and mechanism of action has remained elusive. Here we show that phosphorylation of 
Y640 is involved in the negative regulation of STAT3 transcriptional activity in response to different cytokines. 
Remarkably, only the kinase domain of TYK2 and not of the other JAK kinases is able to catalyze this alternative 
phosphorylation.
Results
The TK domain of TYK2 induces STAT3 dual tyrosine phosphorylation. The STAT3 sequence is 
extremely conserved, including all the tyrosine residues. Analysis of the available STAT3 crystal structures learns 
that most tyrosines are at least partially solvent-exposed at the protein surface and could be targeted by posttrans-
lational modifications such as phosphorylation. For instance, Y705 is known to be phosphorylated upon receptor 
triggering and pY705 is required for formation of parallel activated STAT3 homodimers, nuclear translocation 
and STAT3-dependent gene transcription36–39. To test whether additional tyrosines could be targeted by the JAKs, 
we used an unbiased approach by transiently co-expressing constitutively active tyrosine kinase domains (FLAG-
TKs) of JAK1, JAK2, JAK3 or TYK2 together with either wild type (wt) or Y705F mutant E-tagged-STAT3 in 
HEK293T cells. Immunoprecipitation analysis demonstrated that, as expected, all four JAK TKs can induce Y705 
phosphorylation of wt STAT3 (Fig. 1a) with stronger signals for TYK2 and JAK2 compared to JAK1 and JAK3. 
Remarkably, only inclusion of TYK2 TK revealed the existence of an additional tyrosine phosphorylation site in 
STAT3 Y705F when probing with a monoclonal anti-pY antibody (Fig. 1a).
PDBe PISA40 analysis of the STAT3 crystal structure41 indicates that two tyrosines of the SH2 domain are bur-
ied in the STAT3 dimerization interface (Fig. 1b). Y640 of one STAT3 is present in the binding cleft of the peptide 
sequence immediately downstream of Y705 of the other STAT3 and 23 Å2 of its surface becomes buried below 
T708 upon STAT3 dimerization. Y657 is present close to this binding cleft, but this residue is less solvent exposed 
and only 0.29 Å2 of its surface becomes buried after STAT3 dimer formation. Molecular modelling indicates 
that the phosphorylation of Y640 is likely to interfere with STAT3 dimerization (Fig. 1c): the phosphate intro-
duced at Y640 partially occupies the binding site for T708, a threonine that was already shown to be important 
for STAT3-DNA complex formation42. Given the crucial role for the pY705-SH2 domain interaction43 we next 
performed a similar IP analysis as described above using wt or Y705F Etag-STAT3 carrying the additional Y640F 
or Y657F mutations. As shown in Fig. 1d, immunoblotting using the anti-pY antibody showed complete loss of 
the TYK2 TK-induced phosphorylation signal, only in case of the double Y640F-Y705F mutant. Taken together, 
these data provide evidence for a TYK2-driven phosphorylation of Y640, in addition to phosphorylation of the 
canonical Y705 motif.
Mutation of Y640 enhances formation and stability of activated STAT3 homodimers in 
response to IFNα2. We next analysed whether the Y640F mutation may affect the ligand-induced homod-
imerization status of STAT3. E-tagged and YFP-tagged versions of either STAT3 wt or STAT3 Y640F were tran-
siently co-expressed in HEK293T cells. Cells were treated with IFNα2 or LIF for 15 minutes and Etag-STAT3 
(either wt or mutant) was immunoprecipitated. Western blot analysis was used to reveal STAT3 phosphorylation 
and dimerization. As expected, both IFNα2 and LIF stimulation induced phosphorylation and dimerization of 
wild-type STAT3 and this was further enhanced when combining the STAT3 Y640F mutants (Fig. 2). The effect 
is however more pronounced for IFNα2, which is in line with TYK2 being a key JAK kinase of the IFN recep-
tor (IFNAR) complex (Fig. 2, upper panel, lane 5 versus lane 2). Interestingly, the input control demonstrates 
enhanced phosphorylation of Y705-STAT3 in the untreated condition, only when STAT3 is mutated at Y640 
(Fig. 2, lower panels, lane 4). This observation is completely in line with earlier findings by Pilati et al.31 that in 
the presence of STAT3 Y640F a significant fraction of STAT3 is constitutively phosphorylated and dimerized. 
To conclude, STAT3 Y640F leads to enhanced phosphorylation of STAT3 at Y705 and to increased dimerization 
particularly after IFNα2 stimulation.
STAT3 Y640F shows increased nuclear translocation and binding at the SOCS3 promoter. We 
next analyzed the effect of the Y640F mutation on STAT3 nuclear translocation and DNA binding using immu-
nofluorescence and chromatin immunoprecipitation (ChIP), respectively. We focused on IFNα2, given the pro-
nounced promoting effects of STAT3 Y640F on formation of activated homodimers as observed above. We found 
that the IFNα2-induced nuclear accumulation of STAT3 was significantly faster in HEK293T cells transiently 
transfected with Etag-STAT3 Y640F compared to Etag-STAT3 wt expressing cells. The latter cells showed a clear 
nuclear accumulation only upon 15 min of stimulation with IFNα2 (Fig. 3a). Of note, at later time points (1h-2h) 
we observed distinct nuclear and perinuclear STAT3 speckles only in STAT3 Y640F mutant transfected cells. 
As expected, no nuclear translocation was observed for the STAT3 dominant negative Y705F mutant (data not 
shown).
ChIP assays were performed on HEK293T cells transiently expressing Etag-STAT3 wt or the Etag-STAT3 
Y640F, Y705F, Y640F/Y705F mutants. Cells were stimulated with either IFNα2 or LIF and as a representative 
model for STAT3-binding we studied recruitment to the endogenous SOCS3 promoter. As shown in Fig. 3b, both 
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Figure 1. The TYK2 TK domain specifically mediates alternative STAT3 tyrosine phosphorylation. (a) HEK293T 
cells were transiently co-transfected with control plasmid (C.V.) or plasmids coding for Etagged-STAT3 WT or 
Y705F and FLAG-tagged JAK TK domains. STAT3 was immunoprecipitated with an anti-Etag antibody and 
the membrane was probed using general anti-phospho-tyrosine, anti-phospho-STAT3 (pY705) and anti-Etag 
antibodies (panels denoted IP). Total cell lysates were collected before immunoprecipitation, similar amounts of 
protein extracts were blotted for each condition, as quantified using a Bradford (Bio-Rad) assay and the membrane 
was probed with anti-phospho-STAT3 (pY705), anti-Etag, anti-β-actin and anti-FLAG antibodies (panels 
denoted INPUT). n = 2, representative figures. Full-length blots are presented in Supplementary Figs S6–S7. Y640 
phosphorylation affects STAT3 dimer formation. (b) SH2 domain of STAT3 (blue) with a bound phosphopeptide 
(pY705) of an interacting STAT3 molecule (beige). T708 and the phosphorylated Y705 of the phosphopeptide 
are indicated. The hydroxyl group of Y640 and Y657 (red) are in close proximity of the binding site for this 
phosphopeptide. (c) Phosphorylation of Y640 leads to a clash Model of the SH2 domain with a phosphorylated 
Y640. A STAT3 phosphopeptide was placed in the SH2 domain, as in panel A. This leads to clashes between 
T708 and the phosphate group of Y640, indicating that Y640 phosphorylation is likely to affect the binding 
mode with the pY705 phosphopeptide. (d) Alternative phosphorylation involving STAT3 Y640. HEK293T cells 
were transfected with increasing amounts of plasmids coding for FLAG-tagged TYK2 TK domain and different 
Etagged-STAT3 wt or mutants: STAT3Y705F; STAT3 Y640F; STAT3 Y640F Y705F; STAT3 Y657F; STAT3 Y657F 
Y705F. STAT3 was immunoprecipitated with an anti-Etag antibody and the membrane was probed using anti-
phospho-tyrosine and anti-phospho-STAT3 (pY705) antibodies (panels denoted IP). For the input, total cell 
lysates were collected before immunoprecipitation and similar amounts of protein extracts were blotted for each 
condition, as quantified using a Bradford assay and the membrane was probed with anti-phospho-STAT3 (pY705), 
anti-Etag, anti-β-actin and anti-FLAG antibodies (panels denoted INPUT). n = 2, representative figures. Full-
length blots are presented in Supplementary Figs S8–S9.
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treatments induced a much more pronounced recruitment of STAT3 Y640F compared to STAT3 wt. The Y705F 
mutant and the dual mutant Y640F/Y705F showed no signs of SOCS3 promoter binding. For all the condition 
tested there was no evidence for binding at the endogenous promoter of the non STAT3-responsive HPRT gene 
(Suppl. Data Fig. S1). In conclusion, our data show that the Y640F mutation speeds up the nuclear translocation 
of STAT3 dimers following IFNα2 treatment, facilitating an enhanced binding to the STAT3-responsive gene 
SOCS3. EMSA experiments confirmed the results obtained by ChIP analysis using SOCS3 and cFOS promoter 
sequences as probes. In concordance with the ChIP experiments, the STAT3 Y640F mutant showed enhanced 
binding to the probes as compared to STAT3 wt upon both IFNα2 and LIF stimulation (Suppl. Data Fig. S2).
Expression of the STAT3 Y640F mutant restores IFNα2-dependent STAT3 transcriptional activ-
ity. STAT3-driven gene transcription has been shown to be tightly controlled by cell-specific events, includ-
ing post-translational modifications. We previously reported that in HEK293T cells, transcriptional activity of 
STAT3 was undetectable upon stimulation with IFNα244, in marked contrast to LIF, although Y705 phosphoryl-
ation was comparable for both stimuli. In this context and given the abovementioned critical role of TYK2, we 
wondered whether phosphorylation of STAT3 Y640 could serve as an inhibitory phosphorylation event ham-
pering STAT3-dependent gene expression upon type I IFN signalling. We first evaluated the well-documented 
STAT3-responsive rPAP1-luciferase reporter45. HEK293T cells were transiently co-transfected with the reporter 
vector, a plasmid coding for the IL-6Rα chain and one of the following Etag-STAT3 constructs: wt, Y705F, Y640F, 
Y640F/Y705F, Y657F or Y657F/Y705F, followed by stimulation with IFNα2, LIF or IL-6. Interestingly, we found 
that the presence of the Y640F mutant strongly increased reporter activity for all cytokines tested, but the effect 
was far most pronounced for IFNα2, with an induction comparable to the other cytokines (Fig. 4a,b).
Further experiments also showed that expression of Y640F mutant in murine N38 and NIH3T3 cells, tran-
siently co-transfected with the STAT3-responsive rPAP1-luciferase reporter, leads to a pronounced increase of 
STAT3 transcriptional activity upon IFNα or LIF treatment compared to cells expressing STAT3 wt thus provid-
ing evidence that cell lines other than HEK293T have a similar regulatory mechanism involving STAT3 phospho-
rylation at Y640 (Suppl. Data Figs S3–S4).
This upregulation was specific for the Y640F mutation since no transcriptional enhancement was observed for 
the Y657F mutant. Expression of STAT3 wt led to moderately increased SOCS3 expression upon LIF stimulation 
and to some extent also after IFNα2 stimulation, in accordance with previous studies showing restoration of 
IFNα2-dependent STAT3 transcriptional activity in HEK293T cells overexpressing STAT3 (data not shown). We 
further evaluated the effect of the phospho-mimicking STAT3 Y640E mutant on activation of the rPAP1 reporter 
(Fig. 4c,d). HEK293T cells expressing the Y640E mutant showed strongly impaired LIF-dependent reporter tran-
scription, comparable to the Y705F mutant, further illustrating the dominant negative activity of this mutant on 
activated endogenous STAT3.
Next, we also measured transcriptional activity by qPCR for the endogenous STAT3-responsive SOCS3 
gene in HEK293T cells transiently transfected with STAT3 wt or mutants and stimulated with either IFNα2 or 
Figure 2. Enhanced IFNα2-induced homodimerization of the STAT3 Y640F mutant. HEK293T cells 
were transiently transfected either with the combination of Etag-STAT3wt and STAT3wt-YFP or with 
the combination of Etag-STAT3 Y640F and STAT3 Y640F-YFP. Cells were serum starved 6 hours and 
then stimulated for 15 minutes with 5 ng/ml IFNα2 or 20 ng/ml LIF, or left untreated. Etag-STAT3 was 
immunoprecipitated with an anti-Etag antibody. Total STAT3 and phosphorylated STAT3 were revealed with an 
anti-STAT3 and anti-STAT3 pY705 antibodies, respectively (panels denoted IP). Total cell lysates were collected 
before immunoprecipitation, protein concentration was determined by Bradford assay and similar amounts 
of protein extracts were blotted for each condition, using antibodies as indicated in the Figure (panels denoted 
INPUT). n = 3, representative figures. Full-length blots are presented in Supplementary Figs S10–S11.
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LIF. Importantly, a dramatic increase was again observed when expressing the STAT3 Y640F mutant, whereby 
IFNα2-dependent transcription almost equalled the increased LIF-induced transcription (Fig. 4e). In the same 
experiment, expression of Y705F and Y640F-Y705F mutants led to reduced LIF-induced SOCS3 transcription. 
Type I IFNs also activates another STAT dependent signalling cascade relying on STAT1, STAT2 and IRF9 which 
form the ISGF3 complex46. Transcription of the ISGF3-responsive genes IFITM1 (Fig. 4f) and 2′5′OAS (Suppl. 
Data Fig. S5) was unaffected by wt or mutant STAT3 expression. Taken together, our results show that phos-
phorylation of Y640 is an inhibitory posttranslational modification. In accord, mutation hereof can enhance 
STAT3-dependent transcription, and, in case of type I IFN signalling, can even override a complete transcrip-
tional block.
Discussion
The precise role of STAT3 in type I IFN signaling has been a matter of debate due to the complex nature of STAT3 
itself and to its diverse functions that strongly depend on the cellular context47–53. STAT3 has been shown to 
mostly promote proliferation, cell cycle progression and survival54 whilst type I IFN-driven transcription involves 
genes with often pro-apoptotic activities55, indicating that mechanisms must exist to fine tune the transcriptional 
activity of STAT3 in a cytokine- and cell-dependent way. We previously reported that the transcriptional activity 
of IFNα2-activated STAT3 can be regulated at the nuclear level by the Sin3a co-repressor complex that exerts an 
inhibitory activity downstream of STAT3-DNA binding44. We showed that IFNα2 stimulation leads to STAT3 
Figure 3. The STAT3 Y640F mutation influences STAT3 subcellular distribution in response to IFNα2. (a) 
HEK293T cells were transiently transfected with empty vector (Control Vector), Etag-STAT3 wt or Etag-STAT3 
Y640F mutant. Cells were starved for 16 hours and then either left unstimulated (NS) or stimulated with IFNα2 
(10ng/ml) for the indicated times. Cells were fixed, stained with DAPI and anti-Etag and the localization of 
STAT3 was assessed by confocal analysis. Immunofluorescence of representative cell fields is shown. Enhanced 
IFNα2-induced DNA binding of the STAT3 Y640F mutant. (b) ChIP assays were performed to examine the 
occupancy of STAT3 on the SOCS3 promoter. HEK293T cells were transiently transfected either with empty 
vector (Control Vector) or different Etag-STAT3 mutants: STAT3Y705F; STAT3 Y640F; STAT3 Y640F/Y705F. 
Cells were serum starved 4 hours and then left unstimulated (NS) or stimulated for 1 hour either with 10ng/
ml IFNα2 or LIF. Immunoprecipitated DNA was used for qRT-PCR using specific primers for the SOCS3 
promoter. Graphs represent occupancy levels relative to irrelevant IgG immunoprecipitated DNA samples. All 
results are representative of 3 independent experiments. Error bars indicate SD. **P < 0.01, ***P < 0.001; 1-way 
ANOVA with Bonferroni test.
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Figure 4. Mutation of STAT3 at Y640 restores IFNα2-induced STAT3 transcriptional activity. (a) Left panel: 
HEK293T cells were transiently transfected with the pXP2d2-rPAP1-luciferase reporter together with the 
plasmid coding for the IL-6Rα chain and the control plasmid (Control Vector) or plasmids coding for different 
Etag-STAT3 mutants: STAT3Y705F; STAT3 Y640F; STAT3 Y640F Y705F; STAT3 Y657F; STAT3 Y657F Y705F. 
Cells were left unstimulated (NS) or stimulated for 24 hours with 10ng/ml IFNα2 or LIF or with 100ng/ml 
IL-6. Luciferase readout is expressed as a ratio between stimulated and unstimulated values. All results are 
representative of 3 independent experiments. Error bars indicate SD. *P < 0.05, **P < 0.01, ***P < 0.001; 
Student t-test. (b) Right panel: total cell extracts were blotted and membranes were probed with anti-STAT3, 
anti-Etag and anti-β-actin antibodies. Full-length blots are presented in Supplementary Fig. S12. (c) HEK293T 
cells were transiently transfected with the pXP2d2-rPAP1-luciferase reporter together with the control plasmid 
(Control Vector) or plasmids coding for different Etag-STAT3 mutants: STAT3Y705F; STAT3 Y640E. Cells 
were left unstimulated (NS) or stimulated for 24 hours with 10ng/ml IFNα2 or LIF. Luciferase readout is 
expressed as a ratio between stimulated and unstimulated values. All results are representative of 2 independent 
experiments. Error bars indicate SD. *P < 0.05, **P < 0.01; Student t-test. (d) Total cells extracts were blotted to 
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phosphorylation, nuclear translocation and DNA-binding comparable as observed upon LIF treatment but with-
out inducing a comparable transcriptional activity. Sin3a was found to function as a scaffold for other proteins in 
the complex by directly interacting with acetylated STAT3 thereby promoting STAT3 deacetylation and inhibiting 
STAT3-driven gene transcription56. Acetylation together with phosphorylation and other post-translational mod-
ifications (PTMs) have been reported to influence STAT3 signaling, possibly involving cross-talk mechanisms, 
that ultimately govern the complex modulation of STAT3 activity57,58. Our findings now point to a surprising new 
role for TYK2 as a kinase that can impair STAT3 transcriptional activity. Enhanced STAT3 reporter activation and 
gene transcription are observed for IL-6 and LIF, which signal through gp130-based receptor complexes, but the 
enhanced transcriptional effect upon mitigation of the TYK2-targeted phosphorylation site is most pronounced 
in response to IFNα2. This is not unexpected since TYK2 is the key kinase associated to the IFNAR1 chain of the 
IFNAR complex. This is in contrast to signaling through gp130-based cytokine receptors complexes, which rely 
mainly on JAK1-JAK2 activity, where TYK2 functions more like a bystander kinase59–64.
In line with these findings, only the TK domain of TYK2 and not of any other JAK was capable of inducing an 
alternative phosphorylation in STAT3 Y705F mutant co-expressing cells. This led us to hypothesize the presence 
of an alternative STAT3 phosphorylation site which, based on structural considerations involved in engaging 
the active STAT3 dimer, was identified as the Y640 residue. Its critical role in down-modulating STAT3 tran-
scriptional activity was subsequently demonstrated using dimerization, nuclear translocation, ChIP, reporter and 
qPCR assays using the Y640F STAT3 mutant. In line with a receptor-proximal control mechanism, we could not 
detect any variability on histone acetylation or any variation of co-factor recruitment on the SOCS3 promoter, as 
a consequence of the Y640F mutation (data not shown). Of note, phospho-specific antibodies directed against 
pY640 cross-react with the pY705 site and vice versa, since both are embedded in a highly similar sequence 
motif. Y640 phosphorylation can thus only be detected using a Y705F mutant and not using wt STAT3, possi-
bly explaining why this regulatory phosphosite has remained undetected so far. Notwithstanding, the STAT3 
Y640F mutation was already described as one of the most common STAT3 somatic mutations associated with the 
onset of several cancers, both hematological and solid31,32. Y640F mutated STAT3 was found to be constitutively 
phosphorylated at tyrosine 705 and to dimerize in absence of any stimulus. Moreover, STAT3 Y640F showed a 
hyper-responsiveness to IL-6 treatment, as compare to STAT3 wt, with an increased transcription of its down-
stream target genes. IL-6 dependent phosphorylation at S727 was not increased in STAT3 Y640F when compared 
to IL-6 activated STAT3 wt31. These results show that Y640 is a key residue in modulating STAT3 activity and thus 
can be target of a negative regulatory phosphorylation event. In this study, we demonstrate that STAT3 Y640F is 
able to respond to IFNα2 showing accelerated nuclear translocation and increased DNA-binding, as compared to 
IFNα2-activated STAT3 wt, ultimately resulting in a remarkable IFN-dependent transcriptional activity. In line 
with our findings, it was recently reported that in anaplastic large cell lymphomas (ALCLs) constitutively active 
Tyk2 fusion proteins are oncogenic by driving the STAT3 signaling pathway65.
Tyrosine 640 is located in the inside a PYTK sequence motif conserved in STAT1, STAT2, STAT3 and to a 
lesser extent in STAT4. Interestingly, in STAT5α, STAT5β and STAT6 the tyrosine residue within this motif is 
replaced by a phenylalanine residue. The importance of STAT2 Y631 (the equivalent of STAT3 Y640) has been 
already described showing that mutating this residue to phenylalanine leads to resistance to dephosphorylation 
by the nuclear tyrosine phosphatase TcPTP and thus to sustained IFN-dependent STAT1 Y701 phosphorylation, 
STAT1-STAT2 Y631F heterodimerization and induction of ISGF3-responsive genes with consequent enhanced 
cell apoptosis66. It has already been reported that STAT molecules can be found intracellularly as preformed 
dimers in a latent and unphosphorylated state67,68. In the same context, STAT3 was found to have a peculiar 
behavior in being the only STAT protein with two different parallel orientations: one for the latent dimers and 
one for the activated dimers, both different from the antiparallel orientation of the latent dimers of STAT1 and 
STAT569. In STAT3, Y640 can be targeted by a downregulating phosphorylation, impairing the molecular switch 
needed for the formation of a parallel activated dimer from a parallel latent dimer. Conversely, the Y640F muta-
tion is predicted to result in a more hydrophobic surface32 which might lead to an enhanced stability of activated 
STAT3 dimers.
The activity of IFN-activated STAT3 varies in a cell context-dependent way. Indeed, depending on the 
cell type, the level of IFN-induced STAT3 phosphorylation is not followed by a comparable activation of 
STAT3-responsive genes, whilst in others STAT3 can induce ISGs transcription in response to IFNs. This is 
supported by a number of studies concerning IFN-driven antiviral and antiproliferative effects in IFN-resistant 
Daudi cells70, IFN-dependent pro-apoptotic activity in primary murine pro-B cells71 and IFNα-dependent inhi-
bition of viral replication of Influenza and Vaccinia viruses in STAT3-/- Murine Embryonic Fibroblasts (MEFs)72. 
On the basis of these observations one might speculate about the existence of cell-context dependent fine-tuning 
of IFN-induced STAT3 activity by e.g. a protein tyrosine phosphatase acting on Y640 phosphorylated STAT3 and 
releasing the IFN-specific transcriptional brake on STAT3. Finally, Src kinases are also known to regulate STAT3 
phosphorylation and therefore STAT3 activity. We could however rule out a role for Src kinases since the selective 
test transfection efficiencies and the membranes probed with anti-STAT3, anti-Etag and anti-β-actin antibodies. 
Full-length blots are presented in Supplementary Fig. S13. qRT-PCR analysis representing the relative mRNA 
levels of genes (e) SOCS3 and (f) IFITM1. HEK293T cells were transiently transfected with empty vector 
(control vector) or different Etag-STAT3 mutants: STAT3Y705F; STAT3 Y640F; STAT3 Y640F Y705F. Cells were 
serum-starved 4 hours and then left unstimulated (NS) or stimulated for 24 hours either with 10ng/ml IFNα2 or 
LIF. Graphs represent the mRNA levels relative to the non-stimulated samples. All results are representative of 3 
independent experiments. Error bars indicate SD. ***P < 0.001; 1-way ANOVA with Bonferroni test.
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inhibitor PP2 did not lead to an upregulation of either IFN- or LIF-induced STAT3-dependent transcriptional 
activity in HEK293T cells transiently expressing either STAT3 wt or STAT3 Y640F (data not shown).
In conclusion, we demonstrate that mitigation of the STAT3 Y640 phosphorylation, as demonstrated by the 
Y640F mutation, renders STAT3 transcriptionally competent in response to IFNα2. We suggest a key role for 
the tyrosine kinase activity of TYK2 in the repression of STAT3 activity. The proposed mechanism may serve to 
fine-tune IFN-specific effects in different cell types.
Materials and Methods
Plasmids, cytokines and treatments. The STAT3-responsive rat pancreatitis-associated protein 1 (rPAP1) 
promoter was used to generate pXP2d2-rPAP1-luciferase reporter as described elsewhere45. The plasmid pMET7-
Etag-STAT3wt was constructed using the primer pair 5′-GCGGCGGCCGCAGCCCAATCAGCTACAG-3′ and 
5′-CGCCTCGAGTCACATGGGGGAGGTAGCGCA-3′ to clone STAT3 into pMET7 vector using NotI-XhoI. By 
site-directed mutagenesis we generated STAT3 mutants starting from pMET7-Etag-STAT3 wt using the 
mutagenesis primers: Y705F 5′-GGTAGCGCTGCCCCATTCCTAAAG ACCAAGTTTATCTG-3′ and 5′-CAGATA 
AACTTGGTCTTTAGGAATGGGGCAGCGCTACC-3′; Y640F 5′-GATCCAGTCCGTGGAACCATTCAC 
AAAGCAGCAACTGAACAACATGTCATT T-3′ and 5′-CAAATGACATGTTGTTCAGTTGCTGCTTTG 
TGAATGGTTCCACGGACTGGAT C- 3′; Y640E 5′-GATCCAGTCCGTGGAACCAGAGACAAAGCAGC 
AACTGAACAACATGT CATTTG-3′ and 5′-CAAATGACATGTTGTTCAGTTGCTGCTTTGTCTCTGGTT 
CCACGGAC TGGATC-3′; Y657F 5′-GAAATCATCATGGGCTTTAAAATCATGGATGC- 3′ and 5′-GCATCC 
ATGATTTTAAAGCCCATGATGATTTC-3′. The TK domains of the four different JAKs were cloned in the 
pMET7-FLAG vector using EcoRI-NotI after PCR with primers: 5′-GACGGAATTCATGGACCCTACG 
GTTTTCCAC-3′ and 5′-GACGGCGGCCGCTCAGCACA CG-3′ (TYK2); 5′-GACGGAATTCATGGACCCC 
ACACATTTTGAAAAGC-3′and 5′-GACGGC GGCCGCTTATTTTAAAAG-3′ (JAK1); 5′-GACGGAATTC 
ATGGATCCTACACAGTTTGAAG AG- 3′ and 5′-GCAGGCGGCCGCTCATCCAGCCATG-3′ (JAK2); 
5′-GACGGAATTCATGCA AGACCCCACGATCTTCGAGGAG-3′ and 5′-GACGGCGGCCGCCTATGAAAA 
GGACAG-3′ (JAK3). Recombinant human IFNα2, recombinant mouse IFNαA (PBL Interferon Source, 
Piscataway, NJ, USA) and recombinant human LIF (Millipore, Billerica, MA, USA) were used at 10 ng/ml, recom-
binant human IL-6 (Peprotech) was used at 100 ng/ml.
Cell culture, plasmid transfection and luciferase assay. HEK293T cells were grown in DMEM + 10% 
FCS and transiently transfected overnight using a standard calcium phosphate precipitation procedure73. For 
immunoprecipitation experiments, 2 × 105 HEK293T cells were seeded in each well of a 6 well plate per condition. 
The next day cells were transfected with 1.5 µg of total plasmid DNA for each well: 0.2 µg of pMET7-Etag-STAT3, 
0.5 µg or 0.1 µg pMET7-FLAG-JAKs TK and 0.7 µg or 1.2 µg empty pMET7 vector. For STAT3 dimerization 
experiments 1 × 106 HEK293T cells were seeded in a 10 cm dish and transfected the next day with 10 µg of total 
plasmid DNA: 0.5 µg of pN.1-STAT3-EYFP (WT or Y640F) and 9.5 µg of pMET7-Etag-STAT3 (WT or Y640F). 
For ChIP experiments, 3 × 106 HEK293T cells were seeded in a 14 cm Petri dish and transfected the next day with 
25 µg of total plasmid DNA for each 14-cm dish: 6 µg of pMET7-Etag-STAT3 and 19 µg empty pMET7 vector. 
For RT-PCR experiments, 2 × 105 HEK293T cells were seeded in each well of a 6 well plate and transfected the 
next day with 1.5 µg of total plasmid DNA: 0.2 µg of pMET7-Etag-STAT3 constructs and 1.3 µg empty pMET7 
vector. For the immunofluorescence analysis 1.5 × 105 Hek293T cells were transfected with 1 µg total DNA in a 
6 well plate: 0.2 µg of pMET7-Etag-STAT3 constructs and 0.8 µg empty pMET7 vector. For the luciferase assay in 
HEK293T cells 1.5 × 105 cells were seeded in each well of a 6 well plate and transfected the next day with 1.5 µg 
total plasmid DNA: 0.2 µg luciferase reporter vector; 0.2 µg expression vector; 0.1 µg pSVL-hIL-6Ra-HAtag cod-
ing IL-6Rα chain; 1 µg empty pMET7 vector. For luciferase assay in murine N38 and NIH3T3 cells 4.5 × 105 cells 
were seeded in each well of a 6 well plate and transfected the next day using Lipofectamine 2000 Transfection 
Reagent (Thermo Fisher Scientific) following the manufacturer’s instructions with 2.5 µg total plasmid DNA: 
0.2 µg luciferase reporter vector; 0.5 µg expression vector; 1.8 µg empty pMET7 vector. The next day cells were 
washed with PBS, trypsinized, transferred to a 96-well plate and left untreated or stimulated with the indicated 
amount of hIFNα2, mIFNαA, hLIF or hIL-6 for 24 h. Luciferase activity was measured by chemiluminescence 
with a TopCount (Canberra-Packard, Waverley, UK) and expressed as fold induction (stimulated/nonstimulated).
Lysate preparation, Immunoprecipitation and Western Blot analysis. 48 h after transfection, 
HEK293T cells from a single 6 well plate were collected, pooled in ice-cold PBS and lysed with 1 ml of modified 
RIPA lysis buffer (200 mM NaCl; 50 mM Tris-HCl, pH 8; 0.05% SDS; 2 mM EDTA; 1% Nonidet P-40; 0.5% sodium 
deoxycholate; 1 mM Na3VO4; 1 mM NaF and complete Protease Inhibitor Cocktail; Roche Applied Science, 
Penzberg, Germany). Cleared lysates were incubated with monoclonal mouse anti-Etag antibody (Phadia) 
overnight at 4 °C. Immune complexes were precipitated by adding 35 µl (50% slurry) of Protein G Dynabeads 
(Thermo Fisher Scientific) and rotated for 3 h at 4 °C. Beads were washed 3 times with modified RIPA buffer, 
resuspended in 30 µl of 5xSDS loading buffer and boiled at 98 °C for 10 min. For STAT3 dimerization experi-
ments, 48 hours after transfection cells were serum-starved for 6 hours and stimulated for 15 minutes with 5 ng/ml 
IFNα or 15 ng/ml LIF, or left untreated. Cells were lysed using 1 mL of modified RIPA buffer (for STAT3 dimers: 
lysates were homogenized with a dounce homogenizer), lysate supernatans were collected and Etag-STAT3 was 
immunoprecipitated using 2 µg mouse anti-Etag (Phadia) and 30 µl (50% slurry) Protein G Dynabeads (Thermo 
Fisher Scientific). Immunoprecipitated proteins were eluted in 2x Laemli buffer and heated at 95 °C for 5 minutes. 
Lysates were loaded on a 10% SDS-polyacrylamide gel and transferred to a polyvinylidene difluoride (PVDF) 
membrane (Millipore). The following antibodies were used: mouse monoclonal anti-phosphotyrosine clone 
4G10 (Millipore); anti mouse monoclonal anti-Etag (Phadia); mouse monoclonal anti-STAT3 (Cell Signaling 
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Technology); rabbit polyclonal anti-phosphorylated Y705 STAT3 (Cell Signaling Technology); mouse monoclo-
nal anti-β-actin (Sigma Aldrich); mouse monoclonal anti-FLAG (Sigma Aldrich); either peroxidase AffiniPure 
goat anti-mouse IgG or peroxidase AffiniPure goat anti-rabbit IgG (Jakson, Jakson ImmunoResearch) was used 
as secondary antibody. SuperSignal pico Chemiluminescent Substrate (Thermo Fisher Scientific) was used as 
substrate of peroxidase and targeted proteins on the blot were visualized using CL-XPosure films (Thermo Fisher 
Scientific).
Chromatin Immunoprecipitation (ChIP) assays. 48 hours after transfection cells were serum-starved 
for 4 hours and stimulated with IFNα2 or LIF for 1 h, followed by fixation with 1% formaldehyde at room temper-
ature for 10 min. Fixation was quenched by addition of 2 M glycine at the final concentration of 10%. Cells were 
washed once, collected in with PBS + 0.5 mM EDTA and centrifuged for 5 minutes 1500 rpm 4 °C. Cell pellets 
were resuspended and sonicated in PBS + 0.5 mM EDTA + 0.5% Nonidet P-40 + complete Protease Inhibitor 
Cocktail to shear the chromatin DNA to fragments of 500–1000 bp. The supernatant was clarified by centrifuga-
tion and 1/10 of the chromatin was saved as input. The remaining chromatin solution was incubated with mouse 
monoclonal anti-Etag (Phadia) or normal mouse Immunoglobulin G (Santa Cruz Biotechnology) at 4 °C over-
night. Antibody-protein-DNA complexes were incubated with 40 µl (50% slurry) Protein G Dynabeads (Thermo 
Fisher Scientific) for 3 h at 4 °C and immunoprecipitates were washed once with RIPA buffer (10 mM Tris-HCl, 
pH 8; 150 mM NaCl; 0.1% NonidetP-40;0.1% sodium deoxycholate; and Complete Protease Inhibitor Cocktail), 
twice with RIPA-500 buffer (10 mM Tris-HCl, pH 8; 500 mM NaCl; 0.1% SDS; 1% Nonidet P-40; 0.1% sodium 
deoxycholate; and Complete Protease Inhibitor Cocktail), once with LiCl buffer (10 mM Tris-HCl, pH8; 250 mM 
LiCl; 0.5% Nonidet P-40; 0.5% sodium deoxycholate; 1 mM EDTA and Complete Protease Inhibitor Cocktail) 
and one last time with TBS buffer (20 mM Tris-HCl, pH7.6 and 137 mM NaCl). Immune complexes were eluted 
from beads using elution buffer (1% SDS; 0.1% NaHCO3) at room temperature while shaking. Cross-linking was 
reverted by incubation at 67 °C overnight. All samples were treated with 50 ng/µl of RNase A and 100 ng/µl of 
Proteinase K. DNA fragments were purified using the QIAquick PCR purification kit (Qiagen) and subjected to 
quantitative PCR using SYBR Green Master (Roche Applied Science) with the specific primer pair for the SOCS3 
promoter 5′-AAAAGGGGAAGGGGAACC-3′ and 5′-GGAGAGCGGGCAGTTCTA-3′. The results were ana-
lyzed using the ∆∆CT method. The fold change of STAT3 promoter occupancy was calculated by normalizing 
the relative amount to the input and comparing with normal mouse Immunoglobulin G precipitated chromatin.
Quantitative RT-PCR (qRT-PCR). Cell lysates were homogenized with the QiaShredder Column (Qiagen) 
and total cellular RNA was extracted using RNasy Mini kit (Qiagen) following the manufacturer’s instruc-
tions. Equal amounts of RNA (1 µg) were used for reverse transcription using the Primescript RT Reagent kit 
(Takara Bio) following the manufacturer’s instructions. cDNA was then diluted 1:20 and amplified in quanti-
tative PCR which was monitored using Lightcycler 480 SYBR Green I Master (Roche Diagnostics, Belgium) 
in a LightCycler 480 Real-Time PCR System thermocycler (Roche Applied Science) and the results were ana-
lyzed using the ∆∆CT method. The primers used were as follows: GAPDH 5′-AGCCACATCGCTCAGACAC-3′ 
(forward), 5′-GCCCAATACGACCAAAT CC-3′ (reverse); SOCS3 5′-CTTCGACTGCGTGCTAA-3′ (forward), 
5′-GTAGGTGGCGAGGGG AAG-3′ (reverse); 2′5′OAS 5′-GACGGATGTTAGCCTGCTG-3′ (forward), 
5′-TGGGGATTTGG TTTGGTG-3′ (reverse); IFITM1 5′-CACGCAGAAAACCACACTTC-3′ (forward), 
5′-TGTTCCT CCTTGTGCATCTTC-3′ (reverse); ISG54 5′-TGGTGGCAGAAGAGGAAGAT-3′ (forward), 5′-G 
TAGGCTGCTCTCCAAGGAA-3′ (reverse). The fold change of mRNA expression was calculated by normalizing 
the relative amount to the internal control GAPDH and comparing with untreated cells.
Immunofluorescence analysis and confocal microscopy. 1.5 × 105 HEK293T cells were seeded on 
coverslips previously coated with poly-L-lysine and grown in serum free medium for 16 h. After stimulation 
cells were washed once with PBS + Ca/Mg, fixated 15 minutes in 4% paraformaldehyde and washed three times 
with PBS + Ca/Mg. Cells were permeabilized 10 minutes at −20 °C with ice-cold methanol, washed once in 
PBS + Ca/Mg and incubated with blocking buffer (15.5 mM Na2HPO4; 4.5 mM NaH2PO4; 100 mM NaCl; 0.23% 
Triton X-100; 10% donkey serum) for 1 h and then 16 h at 4 °C with goat anti-Etag (Bethyl Laboratories) (1:2500) 
in blocking buffer. The day after, cells were washed 3 times with washing buffer (15.5 mM Na2HPO4; 4.5 mM 
NaH2PO4; 100 mM NaCl; 0.23% Triton X-100), followed by probing with donkey anti-goat secondary antibody 
(Alexa Fluor 488, Thermofisher Life Technologies) for 45 minutes (1:500) in blocking buffer at room temperature. 
Cells were then washed 3 times with washing buffer and once with PBS + Ca/Mg. 4,6-diamidino-2-phenylindole 
(DAPI) was used to stain the cell nuclei. A motorized inverted IX81 FluoView FV1000 laser scanning microscope 
(Olympus) was used to record high-resolution images.
Molecular modeling. Phosphorylation of Y640 was modeled in YASARA structure74. A phosphate group 
was built on the tyrosine hydroxyl group of a STAT3 monomer (PDB code 1BG1, ref.41), followed by energy min-
imization using the AMBER99 force field. During four minimization steps, atoms within 0.25, 0.5 and 0.75 nm of 
the phosphate phosphorous atom were subsequently allowed to move, followed by minimization of all residues 
with any atom within 0.9 nm of this atom. Via the UCSF Chimera75 matchmaker protocol, the monomer STAT3 
model with Y640 phosphorylation was superposed on the STAT3 dimer found in the crystal structure to test the 
compatibility of Y640 phosphorylation with the dimerization mode in the crystal structure.
Electrophoretic Mobil ity-Shift  Assay (EMSA).  HEK293T cel ls  t ransient ly  t rans-
fected with the desired constructs were starved for 4 h in serum-free medium and were subse-
quently stimulated with 5 ng/ml IFNα2 or 15 ng/ml LIF for 15 min or were left untreated. Protein 
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concentrations of the nuclear extracts were measured with the Bio-Rad protein assay. Double-stranded oli-
gonucleotides based on the cFOS promoter (sense: 5′-GATCCGGGAGGGATTTACGGGAAATGCTG
-3′; antisense: 5′-CTAGGCCCTCCCTAAATGCCCTTTACGAC-3′) and SOCS3 promoter (sense: 
5′-CGATTCCTGGAACTGCGCGG-3′; antisense: 5′-CAGCATTTCCGCGCAGTTCCAGGAA-3′) were 
labelled by filling in 5′ protruding ends with Klenow enzyme using (α-32P) dATP (3000 Ci/mmol; 10 mCi/ml; 
NEN) and purified using the Qiaquick PCR purification kit (Qiagen). Nuclear extracts (5 µg of protein) were 
incubated with approximately 10 fmol (20000 cpm) of probe in gel-shift incubation buffer (10 mM Hepes, pH 
7.8, 1 mM EDTA, 5 mM MgCl2, 10% glycerol, 5 mM dithiothreitol, 2 mM Pefabloc® SC, 1 mg/ml BSA and 0.1 mg/
ml poly(dI-dC)·(dI-dC)) for 10 min at room temperature (25 °C). The supershifting mouse anti-STAT3 antibody 
(Cell Signaling) was incubated with the nuclear extracts for 10 min at room temperature before addition of the 
radiolabeled probe. The protein–DNA complexes were separated on a 4.5% (w/v) polyacrylamide gel containing 
7.5% glycerol in 0.5-fold TBE (Tris/borate/EDTA) at 20 V/cm for 90 min. Gels were fixed in water/methanol/
ethanoic (acetic) acid (80:10:10, by vol.) for 30 min, dried and autoradiographed.
Data Availability Statement. The datasets generated during and/or analysed during the current study are 
available from the corresponding author on reasonable request.
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